Equities

OncoTherapy Science Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

OncoTherapy Science Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)21.00
  • Today's Change1.00 / 5.00%
  • Shares traded33.77m
  • 1 Year change-25.00%
  • Beta0.4961
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

  • Revenue in JPY (TTM)784.25m
  • Net income in JPY-881.65m
  • Incorporated2001
  • Employees47.00
  • Location
    OncoTherapy Science Inc1-2, Higashida-cho, Kawasaki-kuKAWASAKI-SHI 210-0005JapanJPN
  • Phone+81 442016429
  • Fax+81 442016473
  • Websitehttp://www.oncotherapy.co.jp
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ribomic Inc0.00-1.05bn4.67bn25.00--1.36-----23.81-23.810.0063.040.00----0.00-31.15-29.95-32.30-31.15-------2,725.9525.20--0.00-----55.550.5173---6.86--
Modalis Therapeutics Corp0.00-2.06bn5.16bn14.00--1.75-----27.71-27.710.0033.640.00----0.00-66.07-35.65-74.94-36.83-------1,981.18----0.0888------44.90---67.80--
D.Western Therapeutics Institute Inc419.76m-1.06bn5.75bn21.00--3.85--13.70-24.98-24.989.4827.560.19210.41942.7119,988,760.00-48.31-24.39-52.24-26.5889.7593.00-251.53-142.258.69-274.870.2606--10.09-4.07-58.82------
Carna Biosciences, Inc.579.06m-2.17bn5.94bn63.00--19.19--10.25-113.62-113.6230.3016.160.28941.246.17---108.53-37.21-120.28-41.9867.0386.49-375.00-118.286.08-75.550.6979---8.99-12.570.3262---33.02--
TMS Co Ltd0.00-670.20m6.50bn18.00--2.17-----15.72-15.720.0065.780.00----0.00-21.59---22.41----------23.99--0.00------31.20------
Cyfuse Biomedical KK-100.00bn-100.00bn6.83bn21.00--2.30----------298.18------------------------5.80--0.3038---10.91---48.03------
Noile-Immune Biotech Inc7.14m-782.47m7.01bn25.00--1.70--982.06-18.07-18.070.16595.160.00160.000.0668285,720.00-17.08---17.32--30.00---10,954.38--60.62--0.00---97.61--14.65------
Tsubota Laboratory Inc973.21m-172.89m7.30bn17.00--5.65--7.50-6.79-6.7937.6150.080.47330.67264.0057,247,590.00-8.410.1041-12.170.151780.2771.43-17.760.22162.89--0.05860.00101.4925.17132.08132.7026.42--
PRISM BioLab Co Ltd677.33m-833.70m7.35bn35.00--2.70--10.85-22.84-22.8418.5473.590.1779--12.5819,352,290.00-21.90---26.79--39.83---123.09------0.00--121.62--20.56------
OncoTherapy Science, Inc.784.25m-881.65m7.53bn47.00--3.52--9.61-2.93-2.932.605.680.42248.388.7216,686,090.00-47.48-63.66-56.22-77.433.63-0.3852-112.42-184.758.13-832.790.0043--22.9318.8636.71---70.80--
Linical Co Ltd9.87bn-1.19bn7.84bn598.00--1.18--0.7946-52.52-52.52437.00267.760.6226--3.6916,505,640.00-7.482.59-13.504.1921.6129.24-12.023.74----0.258477.26-15.20-0.9283-259.37---42.014.24
Chiome Bioscience Inc593.29m-982.78m7.92bn47.00--6.95--13.35-14.48-14.488.7416.390.28284.979.64---46.84-52.22-59.06-64.4159.9357.59-165.65-174.883.99-1,177.610.1891---24.024.293.72------
Medinet Co Ltd810.29m-1.36bn7.97bn107.00--2.10--9.84-5.15-5.153.0614.270.162814.023.357,572,813.00-27.37-22.42-28.82-23.6413.5417.68-168.10-173.5915.28--0.00--5.440.6867-6.67--10.06--
Chordia Therapeutics Inc0.00-1.46bn8.53bn20.00--3.58-----21.23-21.230.0032.670.00----0.00-46.77---49.97-------------222.950.00------2.26------
BrightPath Biotherapeutics Co Ltd1.11m-1.08bn9.22bn24.00--5.11--8,309.66-11.59-11.590.011713.700.0007----46,250.00-63.35-59.65-74.36-63.7897.6673.74-96,860.36-28,727.67---1,103.910.00--1,473.61-36.871.45---58.41--
Nano Holdings Inc141.92m-757.17m10.91bn20.00--3.91--76.90-10.69-10.692.0136.620.03598.1716.767,095,800.00-18.65-23.68-21.92-25.3772.6482.69-533.54-746.834.10--0.00---19.92-27.80-7.10------
Data as of Feb 13 2026. Currency figures normalised to OncoTherapy Science Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

1.55%Per cent of shares held by top holders
HolderShares% Held
Long Corridor Asset Management Ltd.as of 04 Feb 20265.33m1.55%
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.